NFA
GEVA

Nationwide Fund Advisors’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Nationwide Fund Advisors’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-16,994
Closed -$1.66M – 3433
2015
Q1 		$1.66M Buy
16,994
+774
+5% +$81.9K 0.01% 1596
2014
Q4 		$1.5M Sell
16,220
-175
-1% -$13.8K 0.01% 1581
2014
Q3 		$1.13M Sell
16,395
-39
-0.2% -$2.79K ﹤0.01% 1763
2014
Q2 		$1.72M Buy
16,434
+1,165
+8% +$99.1K 0.01% 1557
2014
Q1 		$1.27M Buy
15,269
+404
+3% +$37.4K 0.01% 1614
2013
Q4 		$962K Buy
14,865
+1,308
+10% +$77.6K ﹤0.01% 1892
2013
Q3 		$858K Sell
13,557
-18,052
-57% -$889K ﹤0.01% 1914
2013
Q2 		$1.33M Buy
+31,609
New +$1.44M 0.01% 1539

Nationwide Fund Advisors's GEVA Position: Q2 2015 in Review

Nationwide Fund Advisors sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 16,994 shares — an estimated $1.66M sold.

Nationwide Fund Advisors first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $1.72M in Q2 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • Nationwide Fund Advisors reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Nationwide Fund Advisors sold 16,994 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $1.66M.
  • Nationwide Fund Advisors first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • Nationwide Fund Advisors's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $1.72M in Q2 2014.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Nationwide Fund Advisors's 13F filing for Q2 2015, filed 29 Jul 2015.